Certara (NASDAQ:CERT) Updates FY 2025 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.420-0.460 for the period, compared to the consensus estimate of 0.500. The company issued revenue guidance of $415.0 million-$425.0 million, compared to the consensus revenue estimate of $422.4 million.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Stephens reaffirmed an “overweight” rating and issued a $17.00 target price on shares of Certara in a report on Thursday. William Blair restated a “market perform” rating on shares of Certara in a research note on Thursday. Robert W. Baird reduced their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. TD Cowen started coverage on shares of Certara in a research report on Thursday. They set a “buy” rating and a $16.00 target price on the stock. Finally, Barclays reduced their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $15.64.

Certara Price Performance

CERT stock traded down $0.55 on Friday, reaching $11.85. The company had a trading volume of 338,357 shares, compared to its average volume of 1,271,024. The company’s fifty day moving average is $12.43 and its 200 day moving average is $11.64. The company has a market cap of $1.91 billion, a P/E ratio of -59.14, a PEG ratio of 9.29 and a beta of 1.57. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. Certara has a 1 year low of $9.41 and a 1 year high of $19.87.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.